Posted by Michael Wonder on 27 Nov 2024
Sparsentan approved to treat adult patients with primary immunoglobulin A nephropathy
18 November 2024 - The MHRA has approved the medicine sparsentan (Filspari) to treat primary immunoglobulin A nephropathy.
Sparsentan was approved under the International Recognition Procedure, following route B.
